Research Publications

PEER-REVIEWED PUBLICATIONS IN INTERNATIONAL MEDICAL JOURNALS

Landmann A, Daniel J Farrugia, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease? Am J Clin Pathol. 2018 May 8. doi: 10.1093

Clark BZ, Daniel J Farrugia, Landmann A, Diego EJ, Dabbs DJ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R. Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. Am J Clin Pathol. 2018 Mar 7;149(4):332-343

Daniel J Farrugia, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R. Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Mod Pathol. 2017 Aug;30(8):1078-1085

Daniel J Farrugia, Fischer TD, Delitto D, Spiguel L, Shaw CM. Improved National Quality Database Breast Cancer Care Metrics Following Implementation of a Standardized Tumor Board Note Template. J. Oncol. Pract 2015 11:209-212

Walker LC, Whiley PJ, Couch FJ, Daniel J Farrugia, Healey S, Eccles DM, Lin F, Butler SA, Goff SA, Thompson BA, Lakhani SR, Da Silva LM; kConFab Investigators, Tavtigian SV, Goldgar DE, Brown MA, Spurdle AB. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Human Mutation. 2010 Jun;31(6):E1484-505.

Daniel J Farrugia, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Research. 2008 May 1;68(9):3523-31.

D’Assoro AB, Busby R, Acu ID, Quatraro C, Reinholz MM, Daniel J Farrugia, Schroeder MA, Allen C, Stivala F, Galanis E, Salisbury JL. Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene. 2008 Feb 11

Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Daniel J Farrugia, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008 Feb 28; 451 (7182): 1116-20

Lovelock P, Spurdle A, Mok M, Daniel J Farrugia, SR Lakhani, S Healey, S Arnold, D Buchanan, kConFab Investigators, FJ Couch, BR Henderson, DE Goldgar, SV Tavtigian, G Chenevix-Trench and M Brown. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Research. 2007 Nov 26;9(6):R82

Wu K, Hinson SR, Ohashi A, Daniel J Farrugia, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Research. 2005, Jan; 65(2):417-26.

Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Daniel J Farrugia, Kaufmann SH, Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Research. 2004, May; 64(10):3517-24.

D’Assoro AB, Busby R, Suino K, Delva E, Almodovar-Mercado GJ, Johnson H, Folk C, Daniel J Farrugia, Vasile V, Stivala F, Salisbury JL. Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint. Oncogene. 2004, May; 23(23):4068-75.

PH.D. THESIS – INHERITED BREAST CANCER

Daniel J Farrugia . Ph.D. Thesis. Influence of inherited missense mutations on BRCA2 function. Functional studies of the DNA-binding domain of BRCA2 (Dec 2007) Mayo Clinic College of Medicine, Rochester, Minnesota

ORAL PRESENTATIONS & INVITED LECTURES

Daniel J Farrugia (October 2006) BRCA2 and Centrosome Dynamics: Centrosome amplification and aberrant function in response to disruption of BRCA2. Mayo Clinic College of Medicine Symposium; Rochester, MN.

Daniel J Farrugia, Walsh MF, Boughey JC. (October 2008) Severe Radiation Changes after Lumpectomy and Radiation for Breast Cancer Requiring Mastectomy with Flap Coverage. Minnesota Surgical Society 2008 Fall Meeting; Alexandria, MN.

Daniel J Farrugia (Sep 10, 2015) Lecture on Breast Cancer to Surgical Oncology Fellows. University of Pittsburgh Medical Center

Daniel J Farrugia (December 2015) Role of Postmastectomy Radiation Therapy in Breast Cancer. Society of Surgical Oncology Breast Fellowship Webinar.

Daniel J Farrugia (April 2016) Functional Classification of Variants of Uncertain Significance in Breast Cancer Predisposition Genes in an Era of Personalized Medicine: Opportunities and Challenges. Invited lecture from Sylvester Comprehensive Cancer Center, University of Miami.

Daniel J Farrugia (October 2016) Breast Surgery. Invited lecture at Centegra Physician Care 2016 Combined Provider Forum. Huntley, IL.

Daniel J Farrugia (February 2017) The evolving personalized medicine approach to breast cancer. Invited lecture at Health Strong Woman Event Lunch and Learn. Crystal Lake, IL.

Daniel J Farrugia (May 2018) A Lymphedema Management Program for Tomorrow. Centegra Sage Cancer Center, McHenry, IL.

SCIENTIFIC ABSTRACTS

Farrugia DJ and Couch FJ. (October 2005) Evaluation of BRCA2 missense mutations in the DNA-binding domain of BRCA2. Mayo Clinic Symposium; Rochester, MN.

Farrugia DJ, Ohashi A, Agarwal MK, and Couch FJ. (July 2006) Cancer Risk Assessment and Functional Evaluation of Inherited BRCA2 Missense Mutations. American Association for Cancer Research Pathobiology of Cancer Meeting; Snowmass, CO.

Farrugia DJ, Goldgar DE, Tavtigian SV, Wadum L, Johnson K, Mentlick J, Lindor N, and Couch FJ. (June 2008) Clinical Classification of BRCA1 and BRCA2 Variants of Uncertain Significance. Department of Defense Era of Hope Breast Cancer Research Program Meeting, Baltimore, MD

Farrugia DJ, Walsh MF, Boughey JC. (October 2008) Severe Radiation Changes after Lumpectomy and Radiation for Breast Cancer Requiring Mastectomy with Flap Coverage. Balfour Surgical Symposium, Mayo Clinic; Rochester, MN.

Farrugia DJ, Goldgar DE, Tavtigian SV, Wadum L, Johnson K, Mentlick J, Lindor N, and Couch FJ. (October 2008) Evaluation of Cancer Causality of BRCA2 Variants of Uncertain Significance. Balfour Surgical Symposium, Mayo Clinic; Rochester, MN.

Farrugia DJ, Diego EJ, Soran A, McAuliffe PF, Landmann A, Bonaventura M, Johnson RR, Ahrendt GM. (November 2015) Institutional Experience of Applying ACOSOG Z0011 Criteria to Breast Cancer Patients Under-Represented in the Z0011 Trial. Women’s Cancer Research Center Retreat, Nemacolin, PA.

Farrugia DJ, Diego EJ, Soran A, McAuliffe PF, Landmann A, Bonaventura M, Johnson RR, Ahrendt GM. Institutional Experience of Applying ACOSOG Z0011 Criteria to Breast Cancer Patients Under-Represented in the Z0011 Trial (ASBrS Annual Meeting in Dallas, April 2016)

Farrugia DJ, Landmann A, Diego EJ, McAuliffe PF, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Puhalla S, Jankowitz R, Brufsky A, Lembersky B, Rastogi P, Davidson NE, Ahrendt GA, Bhargava R. Utilization of Magee Equation 3 in ER Positive, HER2 Negative/Equivocal tumors to Determine Pathologic Response to Neoadjuvant Therapy. (Department of Surgery Research Day, Pittsburgh, May 2016)

Farrugia DJ, Landmann A, Diego EJ, McAuliffe PF, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Puhalla S, Jankowitz R, Brufsky A, Lembersky B, Rastogi P, Davidson NE, Ahrendt GA, Bhargava R. Utilization of Magee Equation 3 in ER Positive, HER2 Negative/Equivocal tumors to Determine Pathologic Response to Neoadjuvant Therapy. (ASCO annual meeting, Chicago; June 2016)

Farrugia DJ, Landmann A, Diego EJ, McAuliffe PF, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Clark B, Puhalla S, Brufsky A, Jankowitz R, Lembersky B, Davidson NE, Ahrendt GA, Bhargava R. Mitotic Index Predicts Breast Cancer Recurrence after Neoadjuvant Systemic Therapy. (ASCO Annual Meeting, Chicago; Jun 2016)

Landmann A, Farrugia DJ, Diego EJ, Bonaventura M, Soran A, Bonaventura M, Johnson R, Dabbs DJ, Clark B, Puhalla S, Brufsky A, Davidson NE, Lembersky B, Jankowitz R, Puhalla S, Ahrendt GA, McAuliffe PF, Bhargava R. HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2 positive or HER2 negative tumors? (ASCO annual meeting, Chicago, Jun 2016)

Landmann A, Farrugia DJ, Diego EJ, Bonaventura M, Soran A, Johnson R, Bonaventura M, Dabbs DJ, Clark B, Puhalla S, Brufsky A, Lembersky B, Jankowitz R, Puhalla S, Ahrendt GA, McAuliffe PF, Bhargava R. Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease? (ASCO annual meeting, Chicago, Jun 2016)

Farrugia DJ, Landmann A, McAuliffe PF, Diego EJ, Johnson R, Bonaventura M, Soran A, Dabbs DJ, Clark B, Lembersky B, Puhalla S, Brufsky A, Jankowitz R, Davidson NE, Ahrendt GA, Bhargava R. Prognostic significance of modified Residual Disease in Breast and Nodes (mRDBN) algorithm after neoadjuvant chemotherapy for breast cancer. (San Antonio Breast Cancer Symposium, San Antonio, Dec 2016)

Lee J, Diego EJ, Soran A, Farrugia DJ, Landmann, A, Bonaventura MB; Johnson R, McAuliffe PF, Ahrendt GM. Neoadjuvant Chemotherapy Increases Breast Conservation Rates and Decreases Extent of Axillary Surgery in Patients with Estrogen Receptor Positive Breast Cancer. (submitted for Society of Surgical Oncology Annual Cancer Symposium, Seattle 2017)

Daniel J Farrugia MD PhD Administrator
Director, Centegra Comprehensive Breast Program
Daniel Farrugia MD PhD is a fellowship-trained board-certified breast surgeon in the northern suburbs of Chicago. He is the Medical Director of the Centegra Comprehensive Breast Program. He trained at Mayo Clinic, the University of Florida, and the University of Pittsburgh. He received several awards for his research in breast cancer which has been published in top international journals, and has been cited over a thousand times in the medical literature.

If you have a suggestion for a future blog post about breast health, please CLICK HERE.
follow me